Factor VIII inhibitors: a clinical overview.
There is much evidence to indicate that inhibitors to Factor VIII in patients with classical hemophilia are the result of an immunological response to exposure to material (VIII:C or VIII:CAg) that is absent or present in reduced amounts in these patients. The inhibitor is an antibody that is usually restricted in immunochemical composition and in many instances contains predominantly or exclusively gamma G3 or gamma G4 heavy chains. Exposure to Factor VIII in many inhibitor patients leads to typical anamnestic responses with marked increases in the level of the inhibitor. The tendency to develop inhibitors and the clinical characteristics of the inhibitor may be affected by genetic factors, basal levels of Factor VIII:C and/or VIII:CAg, and the nature and amount of the "immunizing" material. Currently accepted therapeutic modalities are aimed primarily at the management of acute bleeding episodes.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005169:Factor VIII / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000627:therapeutic use; D005260:Female; D006467:Hemophilia A / Q000097:blood / Q000628:therapy; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged
D005169:Factor VIII